Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review

Joint Bone Spine

Volumn 78, Issue 3, 2011, Pages 279-284

  Baronnet, Laurence ^a   Barnetche, Thomas ^a   Kahn, Valentine ^a   Lacoin, Claire ^a   Richez, Christophe ^a   Schaeverbeke, Thierry ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

Rheumatoid arthritis; TNF antagonist; Tuberculosis

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; HUMAN; INCIDENCE; MEDLINE; MILIARY TUBERCULOSIS; POPULATION; RHEUMATOID ARTHRITIS; RISK; SYSTEMATIC REVIEW; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMORBIDITY; HUMANS; INCIDENCE; RISK FACTORS; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA; WORLD HEALTH;

EID: 79955530517     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.12.004     Document Type: Article

References (27)

1. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155.
2. Recommandations nationales Prévention et prise en charge des tuberculoses survenant sous anti-TNF. Afssaps 2005.
3. Antoine D. Epidemiologie de la tuberculose en France et en Europe. sanitaire Idv 2006.
4. Global tuberculosis control 2008. Surveillance, planning, financing. WHO Organization 2008.
5. Wolfe F., Michaud K., Anderson J., et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004, 50:372-379.
6. Carmona L., Hernandez-Garcia C., Vadillo C., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003, 30:1436-1439.
7. Yamada T., Nakajima A., Inoue E., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 2006, 65:1661-1663.
8. Brassard P., Lowe A.M., Bernatsky S., Kezouh A., Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009, 61:300-304.
9. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52:1766-1772.
10. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261-1265.
11. Baldin B., Dozol A., Spreux A., et al. Tuberculosis and infliximab treatment. National surveillance from January 1, 2000, through June 30, 2003 [Article in French]. Presse Med 2005, 34:353-357.
12. Askling J., Fored C.M., Brandt L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005, 52:1986-1992.
13. Sichletidis L., Settas L., Spyratos D., et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006, 10:1127-1132.
14. Tubach F., Salmon D., Ravaud P., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009, 60:1884-1894.
15. Dixon W.G., Hyrich K.L., Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528.
16. Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006, 43:717-722.
17. Gomez-Reino J.J., Carmona L., Valverde V., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
18. Mohan A.K., Cote T.R., Block J.A., et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004, 39:295-299.
19. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376.
20. Ruyssen-Witrand A., Fautrel B., Saraux A., et al. Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2010, 77:246-251.
21. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412.
22. Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:1157-1160.
23. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
24. Greenberg J.D., Reed G., Kremer J.M., Tindall E., Kavanaugh A., Zheng C., et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010, 69:380-386.
25. Jick S.S., Lieberman E.S., Rahman M.U., Choi H.K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55:19-26.
26. Caramaschi P., Bambara L.M., Pieropan S., et al. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. Joint Bone Spine 2009, 76:333-342.
27. Bruns A., Nicaise-Roland P., Hayem G., et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine 2009, 77:248-253.